Literature DB >> 21700296

Radiotherapy for node positive penile cancer: experience of the Leeds teaching hospitals.

Kevin N Franks1, Kiran Kancherla, Brinda Sethugavalar, Peter Whelan, Ian Eardley, Anne E Kiltie.   

Abstract

PURPOSE: We studied the outcomes in patients with node positive penile cancer who received radiotherapy to inguinal and pelvic nodes. Although half of node positive cases are cured by lymphadenectomy, little data are available on the potential further benefits and toxicities of postoperative radiotherapy.
MATERIALS AND METHODS: We retrospectively audited the clinical notes and electronic records of 23 patients referred to a specialist center from 2002 to 2008 who received radiotherapy to the inguinal/pelvic nodes as adjuvant treatment after lymphadenectomy (14), or as high grade palliation for extensive/fixed nodes (8) or extensive local tumor (1). The primary outcome measure was overall survival. Secondary end points were locoregional recurrence-free survival and toxicity.
RESULTS: All 13 deaths were due to penile cancer. Patients with adjuvant therapy had better overall survival (66% vs 11%, p<0.001) and locoregional relapse-free survival (56% vs 22%, p=0.03) than those with high grade palliation. Six of 14 adjuvant cases and 7 of 9 with high grade palliation relapsed locoregionally. Of patients with adjuvant therapy and extracapsular spread 1 of 6 with N1, 1 of 4 with N2 and 3 of 4 with N3 disease relapsed (p=0.31). No life threatening toxicity was observed. It was difficult to determine the relative contributions of radiotherapy and surgery to leg/scrotal lymphedema. The study was limited by its small size, which reflects the rarity of this tumor.
CONCLUSIONS: Adjuvant radiotherapy appears to have a role after inguinal lymphadenectomy, particularly in patients with extracapsular nodal spread, in whom historically survival rates have been poor. Our findings warrant further investigation in larger series of patients.
Copyright © 2011 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21700296     DOI: 10.1016/j.juro.2011.03.117

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  13 in total

1.  [Neoadjuvant, adjuvant and palliative chemotherapy of penile cancer].

Authors:  C Protzel; A K Seitz; O W Hakenberg; M Retz
Journal:  Urologe A       Date:  2013-11       Impact factor: 0.639

Review 2.  Current Management Strategy for Penile Cancer and Future Directions.

Authors:  Tanya B Dorff; Leslie K Ballas; Anne K Schuckman
Journal:  Curr Oncol Rep       Date:  2017-08       Impact factor: 5.075

3.  Adjuvant pelvic radiation is associated with improved survival and decreased disease recurrence in pelvic node-positive penile cancer after lymph node dissection: A multi-institutional study.

Authors:  Dominic H Tang; Rosa Djajadiningrat; Gregory Diorio; Juan Chipollini; Zhenjun Ma; Braydon J Schaible; Mario Catanzaro; Dingwei Ye; Yao Zhu; Nicola Nicolai; Simon Horenblas; Peter A S Johnstone; Philippe E Spiess
Journal:  Urol Oncol       Date:  2017-06-27       Impact factor: 3.498

Review 4.  Penile cancer: current therapy and future directions.

Authors:  G Sonpavde; L C Pagliaro; C Buonerba; T B Dorff; R J Lee; G Di Lorenzo
Journal:  Ann Oncol       Date:  2013-01-04       Impact factor: 32.976

5.  Bilateral pelvic lymph node dissection for Chinese patients with penile cancer: a multicenter collaboration study.

Authors:  Zai-Shang Li; Chuang-Zhong Deng; Kai Yao; Yong Tang; Nan Liu; Peng Chen; Bin Wang; Xiang Li; Xiao-Feng Chen; Hong Liao; Qi-Wu Mi; Yong-Hong Lei; Qi Zhao; Pei-Zhen Zhao; Xue-Ying Li; Jie-Ping Chen; Qiang-Hua Zhou; Zi-Ke Qin; Zhuo-Wei Liu; Yong-Hong Li; Yun-Lin Ye; Hua Tu; Zi-Jun Zou; Xing Bi; Feng Yang; Ying-Ming Xiao; Jing Li; Xiang-Tian Lin; Wei-Cong Liang; Hui Han; Fang-Jian Zhou
Journal:  J Cancer Res Clin Oncol       Date:  2016-10-22       Impact factor: 4.553

Review 6.  [Surgical treatment of metastatic penile cancer - what is the scientific rationale?]

Authors:  O W Hakenberg; C Protzel
Journal:  Urologe A       Date:  2017-05       Impact factor: 0.639

7.  Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter Analysis.

Authors:  Andrea Necchi; Gregory R Pond; Daniele Raggi; Sarah R Ottenhof; Rosa S Djajadiningrat; Simon Horenblas; Vincent Khoo; Oliver W Hakenberg; Desiree Draeger; Chris Protzel; Axel Heidenreich; Friederike Haidl; Bernie J Eigl; Lucia Nappi; Kazumasa Matsumoto; Ulka Vaishampayan; Michael E Woods; Roberto Salvioni; Nicola Nicolai; Mario Catanzaro; Patrizia Giannatempo; Daniel M Geynisman; Mirko Preto; Evanguelos Xylinas; Matthew I Milowsky; Sabino De Placido; Giuseppe Di Lorenzo; Guru Sonpavde
Journal:  Clin Genitourin Cancer       Date:  2017-02-27       Impact factor: 2.872

8.  Extent of pelvic lymph node dissection in penile cancer may impact survival.

Authors:  Kamran Zargar-Shoshtari; Pranav Sharma; Rosa Djajadiningrat; Mario Catanzaro; Ding-Wei Ye; Yao Zhu; Nicola Nicolai; Simon Horenblas; Philippe E Spiess
Journal:  World J Urol       Date:  2015-05-31       Impact factor: 4.226

9.  The risk factors for the presence of pelvic lymph node metastasis in penile squamous cell carcinoma patients with inguinal lymph node dissection.

Authors:  Jian-Ye Liu; Yong-Hong Li; Zhi-Ling Zhang; Kai Yao; Yun-Lin Ye; Dan Xie; Hui Han; Zhou-Wei Liu; Zi-Ke Qin; Fang-Jian Zhou
Journal:  World J Urol       Date:  2013-02-28       Impact factor: 4.226

10.  The relationship between HPV status and chemoradiotherapy in the locoregional control of penile cancer.

Authors:  Zhigang Yuan; Arash O Naghavi; Dominic Tang; Youngchul Kim; Kamran A Ahmed; Jasreman Dhillon; Anna R Giuliano; Philippe E Spiess; Peter A Johnstone
Journal:  World J Urol       Date:  2018-03-27       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.